NDAINTRAVENOUSSOLUTION
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BLOXIVERZ (neostigmine methylsulfate) by Sagent Pharmaceuticals is inhibitor. First approved in 2013.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLOXIVERZ (neostigmine methylsulfate) is an intravenous acetylcholinesterase inhibitor approved in 2013 for reversal of nondepolarizing neuromuscular blockade during anesthesia recovery. It works by inhibiting acetylcholine breakdown, allowing acetylcholine to accumulate and compete with neuromuscular blocking agents at the neuromuscular junction. This is a critical perioperative agent used in surgical and anesthesia settings.
Peak
Peak lifecycle indicates stable market penetration in operating room protocols; team size likely mature with focus on efficiency and compliance rather than growth expansion.
Mechanism of Action
inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BLOXIVERZ offers a stable, niche career focused on anesthesia relationships and perioperative protocol management rather than broad market development. This product is ideal for professionals seeking deep clinical expertise in a specialized field with lower competitive intensity and relationship-driven selling.
Hospital Account Manager
Worked on BLOXIVERZ at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.